Pharmaceutical Firm Prolius Medicine Submits Listing Application to Hong Kong Exchange

Stock News

02/13

Prolius Medicine (Jiangsu) Co., Ltd. has submitted an application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. According to the prospectus, Prolius Medicine is a leading innovative antimicrobial peptide (AMP) therapeutics company established in April 2009. It focuses on four core therapeutic areas—anti-infectives, metabolic diseases, oncology, and autoimmune diseases—and aims to address significant unmet global health needs through its proprietary breakthrough technologies and drug candidates. As of the latest practicable date, the company has nine drug candidates, including one core product (PL-5) and two key products (PL-3301 and PL-18).

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1171533874"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1171533874\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1171533874?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 20:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171533874","market":"fut","top_or_hot":-1,"title":"Pharmaceutical Firm Prolius Medicine Submits Listing Application to Hong Kong Exchange","media":"Stock News","content":"<p>Prolius Medicine (Jiangsu) Co., Ltd. has submitted an application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. According to the prospectus, Prolius Medicine is a leading innovative antimicrobial peptide (AMP) therapeutics company established in April 2009. It focuses on four core therapeutic areas—anti-infectives, metabolic diseases, oncology, and autoimmune diseases—and aims to address significant unmet global health needs through its proprietary breakthrough technologies and drug candidates. As of the latest practicable date, the company has nine drug candidates, including one core product (PL-5) and two key products (PL-3301 and PL-18).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaceutical Firm Prolius Medicine Submits Listing Application to Hong Kong Exchange</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaceutical Firm Prolius Medicine Submits Listing Application to Hong Kong Exchange\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-02-13 20:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Prolius Medicine (Jiangsu) Co., Ltd. has submitted an application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. According to the prospectus, Prolius Medicine is a leading innovative antimicrobial peptide (AMP) therapeutics company established in April 2009. It focuses on four core therapeutic areas—anti-infectives, metabolic diseases, oncology, and autoimmune diseases—and aims to address significant unmet global health needs through its proprietary breakthrough technologies and drug candidates. As of the latest practicable date, the company has nine drug candidates, including one core product (PL-5) and two key products (PL-3301 and PL-18).</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"開拓藥業-B","start_time":0,"source_url":"","article_id":"1171533874","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171533874","pubTimestamp":1770984975,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Prolius Medicine (Jiangsu) Co., Ltd. has submitted an application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. According to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","09939":"开拓药业-B","BK1161":"生物科技","BK1515":"抗疫概念","BK1574":"生物医药B类股"},"translate_title":"药企Prolius Medicine向港交所提交上市申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"HEXmain":1,"09939":1},"content_text":"Prolius Medicine (Jiangsu) Co., Ltd. has submitted an application for a main board listing on the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. According to the prospectus, Prolius Medicine is a leading innovative antimicrobial peptide (AMP) therapeutics company established in April 2009. It focuses on four core therapeutic areas—anti-infectives, metabolic diseases, oncology, and autoimmune diseases—and aims to address significant unmet global health needs through its proprietary breakthrough technologies and drug candidates. As of the latest practicable date, the company has nine drug candidates, including one core product (PL-5) and two key products (PL-3301 and PL-18).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}